<?xml version='1.0' encoding='utf-8'?>
<document id="21448450"><sentence text="Paliperidone extended-release: does it have a place in antipsychotic therapy?"><entity charOffset="0-12" id="DDI-PubMed.21448450.s1.e0" text="Paliperidone" /></sentence><sentence text="Paliperidone (9-hydroxy-risperidone), the active metabolite of risperidone, was approved for treating schizophrenia worldwide in 2006 as paliperidone extended-release (PER), and became the first second-generation antipsychotic specifically licensed for treating schizoaffective disorder in 2009"><entity charOffset="0-12" id="DDI-PubMed.21448450.s2.e0" text="Paliperidone" /><entity charOffset="14-35" id="DDI-PubMed.21448450.s2.e1" text="9-hydroxy-risperidone" /><entity charOffset="63-74" id="DDI-PubMed.21448450.s2.e2" text="risperidone" /><entity charOffset="137-149" id="DDI-PubMed.21448450.s2.e3" text="paliperidone" /><pair ddi="false" e1="DDI-PubMed.21448450.s2.e0" e2="DDI-PubMed.21448450.s2.e0" /><pair ddi="false" e1="DDI-PubMed.21448450.s2.e0" e2="DDI-PubMed.21448450.s2.e1" /><pair ddi="false" e1="DDI-PubMed.21448450.s2.e0" e2="DDI-PubMed.21448450.s2.e2" /><pair ddi="false" e1="DDI-PubMed.21448450.s2.e0" e2="DDI-PubMed.21448450.s2.e3" /><pair ddi="false" e1="DDI-PubMed.21448450.s2.e1" e2="DDI-PubMed.21448450.s2.e1" /><pair ddi="false" e1="DDI-PubMed.21448450.s2.e1" e2="DDI-PubMed.21448450.s2.e2" /><pair ddi="false" e1="DDI-PubMed.21448450.s2.e1" e2="DDI-PubMed.21448450.s2.e3" /><pair ddi="false" e1="DDI-PubMed.21448450.s2.e2" e2="DDI-PubMed.21448450.s2.e2" /><pair ddi="false" e1="DDI-PubMed.21448450.s2.e2" e2="DDI-PubMed.21448450.s2.e3" /></sentence><sentence text=" However, at the same time, its comparatively high cost gave rise to concerns about the cost-effectiveness of PER as compared with its precursor, risperidone"><entity charOffset="146-157" id="DDI-PubMed.21448450.s3.e0" text="risperidone" /></sentence><sentence text=" This paper reviews the existing knowledge of the pharmacology, kinetics, efficacy, tolerability, and fields of application of PER, and compares PER with risperidone in order to determine whether it has a place in antipsychotic therapy"><entity charOffset="154-165" id="DDI-PubMed.21448450.s4.e0" text="risperidone" /></sentence><sentence text=" An independent assessment of all relevant publications on PER published until July 2010 was undertaken" /><sentence text=" PER has a unique pharmacological profile, including single dosing, predominantly renal excretion, low drug-drug interaction risk, and differs from risperidone in terms of mode of action and pharmacokinetics"><entity charOffset="148-159" id="DDI-PubMed.21448450.s6.e0" text="risperidone" /></sentence><sentence text=" High-level evidence suggests that PER is efficacious and safe in schizophrenia, schizoaffective disorder, and acute manic episodes" /><sentence text=" There is a striking lack of published head-to-head comparisons between PER and risperidone, irrespective of indication"><entity charOffset="80-91" id="DDI-PubMed.21448450.s8.e0" text="risperidone" /></sentence><sentence text=" Low-level evidence shows a lower risk for hyperprolactinemia and higher patient satisfaction with PER than with risperidone"><entity charOffset="113-124" id="DDI-PubMed.21448450.s9.e0" text="risperidone" /></sentence><sentence text=" PER adds to the still limited arsenal of second-generation antipsychotics" /><sentence text=" In the absence of direct comparisons with risperidone, it remains difficult to come to a final verdict on the potential additional therapeutic benefits of PER which would justify its substantially higher costs as compared with risperidone"><entity charOffset="43-54" id="DDI-PubMed.21448450.s11.e0" text="risperidone" /><entity charOffset="228-239" id="DDI-PubMed.21448450.s11.e1" text="risperidone" /><pair ddi="false" e1="DDI-PubMed.21448450.s11.e0" e2="DDI-PubMed.21448450.s11.e0" /><pair ddi="false" e1="DDI-PubMed.21448450.s11.e0" e2="DDI-PubMed.21448450.s11.e1" /></sentence><sentence text=" However, in terms of pharmacology, the available evidence cautiously suggests a place for PER in modern antipsychotic therapy" /><sentence text="" /></document>